Nashville, Tennessee 37212


Purpose:

The goals of this study are to replicate previous findings of genetic predictors of response to clozapine and other antipsychotic drugs.


Criteria:

Inclusion Criteria: Patients with the diagnoses of schizophrenia or schizoaffective disorder, and bipolar disorder or major depression with psychotic features, or volunteers with no history of a psychotic disorder. Exclusion Criteria: Patients with DSM-IV diagnoses other than schizophrenia or schizoaffective disorder, and bipolar disorder or major depression with psychotic features.


NCT ID:

NCT00178932


Primary Contact:

Principal Investigator
Herbert Y Meltzer, M.D.
Vanderbilt University

Barrett Share, M.A.
Phone: 615-936-6796
Email: daniel.b.share@vanderbilt.edu


Backup Contact:

N/A


Location Contact:

Nashville, Tennessee 37212
United States

Kara L Watts, M.A.
Phone: 615-343-9717
Email: kara.l.watts@vanderbilt.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.